Live Breaking News & Updates on Chronic Lymphocytic Leukemia Research Programs

Stay updated with breaking news from Chronic lymphocytic leukemia research programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Gloria Leslie , John Theurer Cancer Center , Chronic Lymphocytic Leukemia Research Programs , Hackensack Meridian School Of Medicine , Indolent Lymphoma , Hackensack Meridian School ,

Pirtobrutinib Approval Adds Effective Third-Line Option to Previously Treated CLL/SLL Armamentarium

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes. ....

United States , New Jersey , Eli Lilly , Gloria Leslie , Hackensack Meridian School Of Medicine , National Comprehensive Cancer Network , Hackensack Meridian Health , Indolent Lymphoma , Chronic Lymphocytic Leukemia Research Programs , John Theurer Cancer Center , Hackensack Meridian School , Hackensack Meridian , Cart Cell Therapy , John Theurer Cancer Center Of Hackensack Meridian Health , Hackensack Meridian School Of Medicine , Third Line ,

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. ....

Gloria Leslie , Chronic Lymphocytic Leukemia Research Programs , Hackensack Meridian School Of Medicine , John Theurer Cancer Center , Indolent Lymphoma , Hackensack Meridian School ,

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma. ....

Gloria Leslie , Chronic Lymphocytic Leukemia Research Programs , Hackensack Meridian School Of Medicine , John Theurer Cancer Center , Indolent Lymphoma , Hackensack Meridian School , John Theurer Cancer Center , Axi Cel , Elderly Patients , Zuma 7 ,

Dr Leslie on Outpatient CAR T-Cell Therapy Programs for Hematologic Malignancies

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced. ....

Gloria Leslie , Chronic Lymphocytic Leukemia Research Programs , Lymphoma Division , Hackensack Meridian School Of Medicine , John Theurer Cancer Center , Indolent Lymphoma , Hackensack Meridian School , John Theurer Cancer Center , Implementing Cart Cell Therapy Programs , Patients With Hematologic Malignancies ,